BSX · News · 20260806N
Guidance / Outlook
BOSTON SCIENTIFIC CORP · 2026-08-06 · Importance 47 · Surprise 60 · In source text
Third-party reporting says Boston Scientific cut its 2026 guidance after weakness in the WATCHMAN business, electrophysiology share losses, and delayed margin improvement. The reports characterize the reduction as postponing a broader recovery toward 2028. No revised revenue, margin, or earnings amounts were provided in the digest.
Key facts
- Boston Scientific cut its 2026 guidance, with the cut attributed to WATCHMAN weakness, electrophysiology (EP) share losses and delayed margin gains. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | Boston Scientific cut its 2026 guidance, with the cut attributed to WATCHMAN weakness, electrophysiology (EP) share losses and delayed… |
| margin | negative | committed | — | Boston Scientific cut its 2026 guidance, with the cut attributed to WATCHMAN weakness, electrophysiology (EP) share losses and delayed… |